Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

569
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
569

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Association Between Number of Hospital Advanced Practice Providers and Surgical Morbidity.

Cancer medicine·2026
Same author

Understanding randomized controlled trial generalizability through an embedded molecular diagnostics trial.

JNCI cancer spectrum·2026
Same author

Acute Hospital Care at Home for Surgical Conditions among Medicare Patients: A National Case Series.

Annals of surgery·2026
Same author

Retraction notice to " Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma"[Clinical Genitourinary Cancer 23/6 (2025) 102422].

Clinical genitourinary cancer·2026
Same author

Accountable Care Organization Efficiency on Entry and Shared Savings Bonuses.

JAMA network open·2026
Same author

Same Day Discharge After Prostatectomy for Prostate Cancer and Readmissions.

Cancer medicine·2026
Same journal

Closing Diabetes Disparities-Is Technology Access Enough?

JAMA network open·2026
Same journal

Clinician Use of Home-Based Medical Care for Medicaid Beneficiaries.

JAMA network open·2026
Same journal

Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.

JAMA network open·2026
Same journal

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma.

JAMA network open·2026
Same journal

Breast Cancer Survival in Asian American Patients.

JAMA network open·2026
Same journal

Social Determinants of Health and Continuous Glucose Monitoring Metrics in Type 1 or Type 2 Diabetes.

JAMA network open·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

435

A Payment Incentive to Improve Confirmatory Testing in Men With Prostate Cancer.

Arnav Srivastava1, Samuel R Kaufman1, Addison Shay1

  • 1Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor.

JAMA Network Open
|September 5, 2025
PubMed
Summary
This summary is machine-generated.

Confirmatory testing for low-risk prostate cancer improved over time. A payment incentive intervention showed a non-significant trend toward increased confirmatory testing, highlighting challenges in value-based care implementation.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

778
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Experiment Videos

Last Updated: Sep 8, 2025

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
05:35

Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

Published on: June 6, 2025

435
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

778
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Area of Science:

  • Urology
  • Health Services Research
  • Oncology

Background:

  • Confirmatory testing is crucial for detecting aggressive prostate cancer in men with favorable-risk disease, yet its use is inconsistent.
  • Value-based interventions and payment incentives are proposed to improve adherence to guideline-concordant care for prostate cancer management.

Purpose of the Study:

  • To evaluate the impact of a multifaceted intervention, including a payment incentive, on confirmatory testing rates in men with low-risk prostate cancer.
  • To assess the effectiveness of a commercial payer's initiative to promote guideline-recommended confirmatory testing.

Main Methods:

  • A cohort study analyzed data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) for men diagnosed with low-risk prostate cancer from January 2017 to July 2022.
  • A payment incentive intervention, coupled with physician education, was implemented between April 2018 and May 2019 to encourage confirmatory testing (MRI, repeat biopsy, or genomics).

Main Results:

  • Confirmatory testing completion increased from 44.6% in 2017 to 64.3% in 2022 (P < .001).
  • During the incentive period, a 7.5% increase in predicted probability of confirmatory testing was observed, though not statistically significant (P = .06).

Conclusions:

  • Confirmatory testing rates for low-risk prostate cancer improved during the study period.
  • The payment incentive intervention did not lead to a statistically significant increase in confirmatory testing, suggesting challenges in implementing such models.
  • Collaboration between payers and physicians can enhance prostate cancer care quality, but requires overcoming implementation hurdles for alternative payment models.